Skip to main content

Advertisement

SpringerLink
Log in

Discovery of 7-bromo-1,4-dihydrothieno[3’,2’:5,6]thiopyrano[4,3-c]pyrazole-3-carboxamide derivatives as the potential epidermal growth factor receptors for tyrosine kinase inhibitors

  • Original Research
  • Published:
Medicinal Chemistry Research Aims and scope Submit manuscript

Abstract

Small molecule tyrosine kinase inhibitors (TKIs) targeting at epidermal growth factor receptor (EGFR) in recent years have made great progress in the treatment of advanced non-small cell cancer (NSCLC). Although as the first-line treatment for sensitizing EGFR mutation-positive metastatic NSCLC, gefitinib has also behaved quite a lot of side effect and EGFR tolerance. Herein, a novel series of 7-bromo-1,4-dihydrothieno[3’,2’:5,6]thiopyrano[4,3-c]pyrazole-3-carboxamide derivatives were designed and synthesized, and screened for their inhibitory activity on the EGFR high-expressing human lung adenocarcinoma cell line A549 and human large cell lung cancer cell line NCI-H460 by using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide colorimetric assay. The calculated IC50 values were reported. Compound 8h demonstrated the most potent inhibitory activity (IC50 = 9.57 ± 2.20 μmol L–1 for A549 and IC50 = 13.04 ± 1.21 μmol L–1 for NCI-H460), comparable to the positive-control gefitinib (IC50 = 8.58 ± 1.65 μmol L–1 for A549 and IC50 = 18.66 ± 5.01 μmol L–1 for NCI-H460). Conclusively, 7-bromo- 1,4-dihydrothieno[3’,2’:5,6]thiopyrano[4,3-c]pyrazole-3-carboxamide derivatives as the EGFR–TKIs were discovered, and could be used as potential leading compounds for further research.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Scheme 1

Similar content being viewed by others

References

  • Adly ME, Gedawy EM, El-Malah AA, El-Telbany FA (2018) Synthesis of novel thieno[2,3-d]pyrimidine derivatives and rvaluation of Theircytotoxicity and EGFR inhibitory activity. Anticancer Agents Med Chem 18(5):747–756

    Article  CAS  PubMed  Google Scholar 

  • Cagniant P, Cagniant D (1966) Contibution àl’étude des hétérocycles soufrés condensés.Dérivés du dihydro-5,6 4H thiéno-[2,3-b]-thiopyranne, du dihydro-5,6 7H thiéno [3,2-b]-thiopyranne et de la tétrahydro-5,6,7,8 thiéno[3,2-b]-thiépinne. Bull Soc Chim Fr 7:2172–2179

    Google Scholar 

  • Coumar MS, Chu CY, Lin CW, Shiao HY, Ho YL, Reddy R, Lin WH, Chen CH, Peng YH, Leou JS, Lien TW, Huang CT, Fang MY, Wu SH, Wu JS, Chittimalla SK, Song JS, Hsu JT, Wu SY, Liao CC, Chao YS, Hsieh HP (2010) Fast-forwarding hit to lead: aurora and epidermal growth factor receptor kinase inhibitor lead identification. J Med Chem 53(13):4980–4988

    Article  CAS  PubMed  Google Scholar 

  • Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, Chao TY, Nakagawa K, Chu DT, Saijo N, Duffield EL, Rukazenkov Y, Speake G, Jiang H, Armour AA, To KF, Yang JC, Mok TS (2011) Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 29:2866–2874

    Article  CAS  PubMed  Google Scholar 

  • Guo ZR (2008) Strategy of molecular drug design: pharmacophore and scaffold hopping. Chin J Med Chem 18:147–157

    CAS  Google Scholar 

  • Inoue A, Saijo Y, Maemondo M, Gomi K, Tokue Y, Kimura Y, Ebina M, Kikuchi T, Moriya T, Nukiwa T (2003) Severe acute interstitial pneumonia and gefitinib. Lancet 361:137–139

    Article  PubMed  Google Scholar 

  • Ke J, Lu Q, Wang X, Sun R, Jin Z, Zhan X, Hu J, Wan DCC, Hu C (2018) Discovery of 4,5-Dihydro-1H-thieno[2′,3′:2,3]thiepino[4,5-c]pyrazole-3-carboxamide derivatives as the potential epidermal growth factor receptors for tyrosine kinase inhibitors. Molecules 23:1980

    Article  CAS  PubMed Central  Google Scholar 

  • Kohno T, Nakaoku T, Tsuta K, Tsuchihara K, Matsumoto S, Yoh K, Goto K (2015) Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer. Transl Lung Cancer Res 4:156–164

    CAS  PubMed  PubMed Central  Google Scholar 

  • Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. New Engl J Med 361:947–957

    Article  CAS  PubMed  Google Scholar 

  • Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immun Methods 65:55–63

    Article  CAS  Google Scholar 

  • National Comprehensive Cancer Network. Non-small Cell Lung Cancer (Version 2, 2016). Available at: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed 2015-12-01

  • Neumann CS, Fujimori DG, Walsh CT (2008) Halogenation strategies in natural product biosynthesis. Chem Biol 15:99–109

    Article  CAS  PubMed  Google Scholar 

  • Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG, Varmus H (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2(3):e73

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Park JH, Liu Y, Lemmon MA, Radhakrishnan R (2012) Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain. Biochem J 448:417–423

    Article  CAS  PubMed  Google Scholar 

  • Parkin DM, Bray FB, Pisani P (2005) Global cancer statistics. CA Cancer J Clin 55(2):74–108

    Article  PubMed  Google Scholar 

  • Ponticello GS, Freedman MB, Habecker CN, Habecker CN, Holloway MK, Amato JS, Conn RS, Baldwin JJ (1988) Utilization of α, β-unsaturated acids as Michael acceptors for the synthesis of thieno[2,3-b]thiopyrans. J Org Chem 1988 53:9–13

    CAS  Google Scholar 

  • Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH (2002) Comparison of four chemotherapy regimens for advanced nonsmall cell lung cancer. New Engl J Med 346:92–98

    Article  CAS  PubMed  Google Scholar 

  • Sharma SV, Bell DW, Settleman J, Haber DA (2007) Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7(3):169–181

    Article  CAS  PubMed  Google Scholar 

  • Sun B, Zhang J, Yin XE, Xu Y, Zhang FR, Huang YS, Wang JH, Wang GQ, Hu C (2016) Synthesis, characterization and biological activity of thieno[2,3-d]pyrimidine derivatives as the epidermal growth factor receptor inhibitors. Lat Am J Pharm 35:570–577

    CAS  Google Scholar 

  • Sun J, Wang XY, Lv PC, Zhu HL (2015) Discovery of a series of novel phenylpiperazine derivatives as egfr tk inhibitors. Sci Rep 5:13934

    Article  PubMed  PubMed Central  Google Scholar 

  • Sun R, Song J, Zhao H, Yan CL, Zhang AJ, Koirala D, Li DW, Hu C (2011) Synthesis and anti-tumor activity of 1,4-dihydrothieno[3’,2’:5,6]thiopyrano[4,3-c]pyrazole-3-carboxamide derivatives. J Chin Pharm Sci 20:26–34

    CAS  Google Scholar 

  • Thomsen R, Christensen MH (2006) MolDock: a new technique for high-accuracy molecular docking. J Med Chem 49(11):3315–3321

    Article  CAS  PubMed  Google Scholar 

  • Wang JJ, Yin BZ, Jiang GJ, Imafuku K (1990) Synthesis of isochroman-fused pyrazolone and pyrimidine derivatives. J Heterocycl Chem 27:1181–1184

    Article  CAS  Google Scholar 

  • Wissner A, Mansour TS (2008) The development of HKI-272 and related compounds for the treatment of cancer. Arch Pharm 2008 341(8):465–477

    CAS  Google Scholar 

  • Wood ER, Shewchuk LM, Ellis B, Brignola P, Brashear RL, Caferro TR, Dickerson SH, Dickson HD, Donaldson KH, Gaul M, Griffin RJ, Hassell AM, Keith B, Mullin R, Petrov KG, Reno MJ, Rusnak DW, Tadepalli SM, Ulrich JC, Wagner CD, Vanderwall DE, Waterson AG, Williams JD, White WL, Uehling DE (2008) 6-Ethynylthieno[3,2-d]- and 6-ethynylthieno[2,3-d]pyrimidin-4-anilines as tunable covalent modifiers of ErbB kinases. Proc Natl Acad Sci USA 105(8):2773–2778

    Article  PubMed  PubMed Central  Google Scholar 

  • Wu CH, Coumar MS, Chu CY, Lin WH, Chen YR, Chen CT, Shiao HY, Rafi S, Wang SY, Hsu H, Chen CH, Chang CY, Chang TY, Lien TW, Fang MY, Yeh KC, Chen CP, Yeh TK, Hsieh SH, Hsu JT, Liao CC, Chao YS, Hsieh HP (2010) Design and synthesis of tetrahydropyridothieno[2,3-d]pyrimidine scaffold based epidermal growth factor receptor (EGFR) kinase inhibitors: the role of side chain chirality and Michael acceptor group for maximal potency. J Med Chem 53(20):7316–7326

    Article  CAS  PubMed  Google Scholar 

  • Zhang HQ, Gong FH, Li CG, Zhang C, Wang YJ, Xu YG, Sun LP (2016) Design and discovery of 4-anilinoquinazoline-acylamino derivatives as EGFR and VEGFR-2 dual TK inhibitors. Eur J Med Chem 109:371–379

    Article  CAS  PubMed  Google Scholar 

  • Zhang L, Deng XS, Zhang C, Meng GP, Wu JF, Li XS, Zhao QC, Hu C (2017) Design, synthesis and cytotoxic evaluation of a novel series of benzo[d]thiazole-2-carboxamide derivatives as potential EGFR inhibitors. Med Chem Res 26(9):2180–2189

    Article  CAS  Google Scholar 

  • Zhao Y, Wu XR, Yin JG, Wang JJ (2002) Synthesis of isochromano[4,3-C]pyrazole substituted with biheterocycle at 3-position. J Yantai Univ Nat Sci Eng Ed 15:113–117

    CAS  Google Scholar 

  • Zhou W, Ercan D, Jänne PA, Gray NS (2011) Discovery of selective irreversible inhibitors for EGFR-T790M. Bioorg Med Chem Lett 21(2):638–643

    Article  CAS  PubMed  Google Scholar 

  • Zhou XF, Guo JL, Ji YM, Pan GF, Liu T, Zhu H, Zhao JP (2016) Reciprocal negative regulation between EGFR and DEPTOR plays an important role in the progression of lung adenocarcinoma. Mol Cancer Res 14:448–457

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by the National Science Foundation of China (NSFC) for the grant No. 21342006 and the Program for Innovative Research Team of the Ministry of Education of China for the grant No. IRT_14R36. We thank Molegro ApS for kindly providing a free evaluation copy of their software package and Schrödinger, LLC for allowing the use of PyMOL Molecular Graphics System.

Author information

Authors and Affiliations

  1. Key Laboratory of Structure-based Drug Design & Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang, 110016, China

    Qian Xie, Jingjing Wang, Miao Liu, Xin Wang, Di Jiao, Qingqing Ma, Zhe Jin, Qingguo Meng & Chun Hu

  2. Department of Pharmacy, Yantai Univeristy, Yantai, 264005, China

    Qingguo Meng

Authors
  1. Qian Xie
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jingjing Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Miao Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xin Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Di Jiao
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Qingqing Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Zhe Jin
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Qingguo Meng
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Chun Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chun Hu.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This article does not contain any studies with animals, performed by any of the authors. Informed consent was obtained from all individual participants included in the study.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Xie, Q., Wang, J., Liu, M. et al. Discovery of 7-bromo-1,4-dihydrothieno[3’,2’:5,6]thiopyrano[4,3-c]pyrazole-3-carboxamide derivatives as the potential epidermal growth factor receptors for tyrosine kinase inhibitors. Med Chem Res 28, 1000–1009 (2019). https://doi.org/10.1007/s00044-019-02354-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00044-019-02354-0

Keywords

Search

Navigation